Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are an antidiabetic class with established cardiovascular benefits and promising effects for T2DM and NAFLD/NASH patients [15]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.